Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Infant Formula NEC Lawsuits Remanded Back to Pennsylvania State Court by MDL Judge The remanded cases all involve lawsuits claims against local hospitals who fed Similac, Enfamil or another cow’s milk-based formula to preterm children, who subsequently developed NEC October 21, 2022 Irvin Jackson Add Your Comments The U.S. District Judge presiding over all infant formula necrotizing enterocolitis (NEC) lawsuits has remanded nearly 30 cases back to state court in Pennsylvania, because those complaints also include claims against local hospitals as defendants, for feeding Similac, Enfamil or other cow’s milk formula to preterm babies. Hundreds of families throughout the U.S. are now pursuing a Similac NEC lawsuit against Abbott Laboratories or Enfamil NEC lawsuit against Mead Johnson, each raising similar allegations that the formula manufacturers recklessly marketed their cow’s milk baby formula for use among premature infants, without disclosing the risk that it may lead to a devastating and life-threatening gastrointestinal disease. Similac and Enfamil have been promoted to hospitals, doctors and families of premature infants as a safe and effective alternative to breast milk, despite a growing body of research which has found the cow’s milk formula substantially increases the risk that preemies will develop NEC, which involves a painful destruction of the bowels that results in the need for emergency surgery while the baby is still in the NICU and often leads to death. BABY FORMULA NEC LAWSUITS Was your premature child fed Similac or Enfamil? Premature infants fed Similac or Enfamil cow’s milk formula face an increased risk of necrotizing enterocolitis (NEC) or wrongful death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION BABY FORMULA NEC LAWSUITS Was your premature child fed Similac or Enfamil? Premature infants fed Similac or Enfamil cow’s milk formula face an increased risk of necrotizing enterocolitis (NEC) or wrongful death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Given similar questions of fact and law raised in NEC lawsuits filed in various different U.S. District Courts nationwide, the U.S. Judicial Panel on Multidistrict Litigation (JPML) established coordinated management for cases earlier this year, centralizing the claims before U.S. District Judge Rebecca R. Pallmeyer in the Northern District of Illinois for centralized discovery and pretrial proceedings. In a Memorandum Opinion and Order (PDF) issued on October 12, Judge Pallmeyer granted a motion to remand 29 infant formula NEC lawsuits originally filed by Pennsylvania residents back to state courts, and remove the claims from the multidistrict litigation. Each of the claims included Pennsylvania hospitals as defendants, including allegations that the medical providers were jointly responsible for the decision to feed Similac, Enfamil or other cow’s milk formula to premature infants. Although the claims were filed in Pennsylvania state court, with a local Pennsylvania-based hospital named as a defendant, the formula manufacturers removed the claims to the federal court system where they were transferred to the MDL pending before Judge Pallmeyer. Abbott Laboratories, which manufactures Similac, objected to the remand, arguing that the local hospitals fradulently joined as defendants, for the sole purpose of keeping claims against the out-of-state formula manufacturers in the Pennsylvania state court system. Although the manufacturer argued that plaintiffs had little chance of prevailing in the NEC lawsuits against the hospitals, Judge Pallmeyer indicated that plaintiffs had a reasonable enough possibility of prevailing to require that the cases be returned back to the state court system. “After reviewing the party’s supplemental briefing, the court now concludes that Abbott has not established that Plantiffs lack any reasonable possibility of prevailing on their claims against the Hospital Defendants,” Judge Pallmeyer wrote. “Plaintiffs’ motions to remand are granted.” October 2022 Infant Formula NEC Lawsuit Update There are currently more than 100 lawsuits pending before Judge Pallmeyer involving claims brought by families nationwide against the makers of Similac and Enfamil. However, as additional claims are filed over the coming years, it is ultimately expected that more than 1,000 will eventually be included in the litigation. To help the parties gauge how juries are likely to respond to certain evidence and testimony that will be repeated throughout the NEC litigation, Judge Pallmeyer has established a “bellwether” program, where a small group of lawsuits will go through case-specific discovery and be scheduled for early trial dates. Following the the bellwether trials, if the parties fail to negotiate NEC lawsuit payouts to settle claims, it is then likely that Judge Pallmeyer will start remanding dozens of individual claims back to U.S. District Courts nationwide for separate trial dates nationwide throughout the federal court system. Tags: Abbott Laboratories, Enfamil, Infant Death, Infant Formula, Mead Johnson, Necrotizing Enterocolitis, Preterm Birth, Similac Find Out If You Qualify for Infant Formula NEC Compensation More Baby Formula Lawsuit Stories Mead Johnson Must Face Enfamil NEC Lawsuit in Missouri State Court July 8, 2025 NEC Formula Lawsuit Set To Go Before Jury in Aug. 2025 June 23, 2025 Enfamil NEC Lawsuit Filed After Newborn Suffers ‘Nearly Total Bowel Necrosis’ June 17, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025) Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025) Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: 2 days ago) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)
Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: 2 days ago) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)